Laboratory:Akiruno
- TOP
- gene-related test
- genetic tests for malignant tumor (solid tumor)
- Lung Cancer Oncomine DxTT Multi 7 Gene CDx (46) FFPE
Laboratory:Akiruno
○Lung Cancer Oncomine DxTT Multi 7 Gene CDx (46) FFPE
CODE:00W82 8
-
TEST NAME
SPECIMEN
REQUIREMENT
(mL) CONTAINER CAP COLOR STORE
TEMPERATURE
(STABILITY) TURNAROUND
TIME (DAY) METHODOLOGY REFERENCE RANGE
(UNIT) -
Lung Cancer Oncomine DxTT Multi 7 Gene CDx (46) FFPE
Unstained specimen slide
5 to 10 sheets
thickness 5μm
Z10
6-9 Next Generation Sequencing (NGS)A method that uses a next-generation sequencer to simultaneously determine the base sequences of a huge number of DNA fragments.
COMMENT
The purpose of this test is to analyze BRAF gene V600E mutations, EGFR gene mutations, HER2(ERBB2) gene mutations, ALK fusion genes,ROS1 fusion genes,RETfusion genes, and METex 14 skipping mutations in genomic DNA and RNA extracted from cancer tissues, and to assist in determining whether drugs listed in the separate table are suitable for non-small cell lung cancer patients. In addition, for research purposes only, we will also report the results of analysis of 46 genes that have not been approved by the Pharmaceutical Affairs.
The required percentage of tumor cells for the tests is 30% or more. Please note the following of the General Testing Guide for important points when submitting unstained specimen slides.
Please avoid duplicate requests with other items. Since the effect of contamination is greater with this testing method, please handle samples with great care when collecting them.
When requesting this test, be sure to also request the nucleic acid extraction item (item code No.0M951 3).
*When submitting unstained specimen slides
-Immediately immerse the collected tissue in 10% neutral buffered formalin solution and fix it (fixation time of approximately 6 to 48 hours is recommended). When submitting, please prepare serial sections at a thickness of 5 μm from the formalin-fixed, paraffin-embedded tissue block.-Unstained specimen slides must be histopathologically evaluated and confirmed that they contain the necessary percentage of tumor cells for the test (the percentage of tumor cells among all cells in the specimen). If the necessary percentage is not met, please mark the tumor cell area on the back of the unstained specimen slide. Please note that submitting unstained specimen slides without marking them may result in false negatives and other adverse effects on the results as macrodissection will not be possible. In addition, please submit unstained specimen slides in an object case (Z10) and store them at room temperature.
-Unstained specimen slides may not be analyzed depending on the type and composition of the fixative, fixation time, and storage conditions of the specimens after fixation, because nucleic acids are fragmented by formalin fixation of the tissue. If possible, please submit samples taken within the past three years. Note that biopsy materials in particular often contain very small amounts of specimen, and the tissue fragments on the paraffin sections may be very small or may not contain tumor cells.
*About biopsy specimens
-Please submit 10 or more slides.
-For samples with a low number of nucleated cells, the necessary amount of nucleic acid may not be obtained, making testing impossible. For small biopsy specimens (tissue section area of 4㎟ [2mm x 2mm or less]), please submit 15 or more slides.
CONTAINER
Z10 旧容器記号 t 30
[オブジェクトケース]
プレパラート (スライドグラス)
貯蔵方法:室温
supplementary information
オンコマインDxTTマルチ検査における対象遺伝子変異等と関連する医薬品および適応がん腫
遺伝子変異等 | がん腫 | 関連する医薬品 |
---|---|---|
BRAF 遺伝子V600E変異 | 非小細胞肺癌 | ダブラフェニブメシル酸塩及びトラメチニブジメチルスルホキシド付加物の併用投与 |
EGFR遺伝子変異 | ゲフィチニブ、エルロチニブ塩酸塩、アファチニブマレイン酸塩、オシメルチニブメシル酸塩、ダコミチニブ水和物 | |
HER2 (ERBB2) 遺伝子変異 | トラスツズマブ デルクステカン (遺伝子組換え) | |
ALK融合遺伝子 | クリゾチニブ、アレクチニブ塩酸塩、ブリグチニブ、ロルラチニブ | |
ROS1融合遺伝子 | クリゾチニブ、エヌトレクチニブ | |
RET融合遺伝子 | セルペルカチニブ | |
METex14 スキッピング変異 | カプマチニブ塩酸塩水和物、テポチニブ塩酸塩水和物 |